Matches in Wikidata for { <http://www.wikidata.org/entity/Q93581660> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q93581660 description "clinical trial" @default.
- Q93581660 description "ensayo clínico" @default.
- Q93581660 description "ensayu clínicu" @default.
- Q93581660 description "klinisch onderzoek" @default.
- Q93581660 description "клінічне випробування" @default.
- Q93581660 description "临床试验" @default.
- Q93581660 name "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 name "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 type Item @default.
- Q93581660 label "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 label "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 prefLabel "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 prefLabel "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer" @default.
- Q93581660 P1132 Q93581660-1BBDB844-77B3-429F-AF77-3C155D341443 @default.
- Q93581660 P1476 Q93581660-4B9752F6-465C-4F1A-AAF5-ACCC35442E2D @default.
- Q93581660 P17 Q93581660-0FB2D641-706B-485A-A3BC-476EB4B67B65 @default.
- Q93581660 P17 Q93581660-181654FE-4BDA-4C4A-AB35-3E7DC11DA40D @default.
- Q93581660 P17 Q93581660-CAB11824-7358-44D9-9512-3C8E57EC5C42 @default.
- Q93581660 P17 Q93581660-DE76D5B1-03EA-419C-8B2E-11D56B7E6C76 @default.
- Q93581660 P1813 Q93581660-7AB1360E-E1EB-4964-8B72-51CE1019FDB2 @default.
- Q93581660 P2899 Q93581660-3F9A09B5-C54E-462E-8AC8-21EF575C8E97 @default.
- Q93581660 P3098 Q93581660-1BB1AD06-0284-4737-8479-5F7BE9062CA3 @default.
- Q93581660 P31 Q93581660-E1ACBCD9-F33E-4BB7-A75A-2480509057ED @default.
- Q93581660 P4135 Q93581660-51809D74-312A-4420-AE70-D13682B39036 @default.
- Q93581660 P4844 Q93581660-7A5E7CEF-B7EC-4AB2-A64E-5E670D964010 @default.
- Q93581660 P4844 Q93581660-8E694A1A-575A-4380-8907-47E395F0462A @default.
- Q93581660 P580 Q93581660-4422FB83-5088-4CC8-B49D-8771958FFEFC @default.
- Q93581660 P582 Q93581660-7D00FBE0-AD4D-4254-82B2-FA6E94B70D6B @default.
- Q93581660 P6099 Q93581660-4CC0EA4D-2A47-4C1C-BFF9-5D0FC2D96B6C @default.
- Q93581660 P8005 Q93581660-7BF299F0-0EE4-4A7C-A8BF-DDE2EA4AF207 @default.
- Q93581660 P8363 Q93581660-62A4A12D-4BEB-4B0F-8DC5-F2B4E44B0F27 @default.
- Q93581660 P859 Q93581660-0F2EE204-8F0F-4B58-9BEB-DFF5187B1949 @default.
- Q93581660 P1132 "+351" @default.
- Q93581660 P1476 "A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer" @default.
- Q93581660 P17 Q17 @default.
- Q93581660 P17 Q298 @default.
- Q93581660 P17 Q869 @default.
- Q93581660 P17 Q881 @default.
- Q93581660 P1813 "NeoADAURA" @default.
- Q93581660 P2899 "+18" @default.
- Q93581660 P3098 "NCT04351555" @default.
- Q93581660 P31 Q30612 @default.
- Q93581660 P4135 "+100" @default.
- Q93581660 P4844 Q415220 @default.
- Q93581660 P4844 Q415588 @default.
- Q93581660 P580 "2020-07-17T00:00:00Z" @default.
- Q93581660 P582 "2024-01-19T00:00:00Z" @default.
- Q93581660 P6099 Q42824827 @default.
- Q93581660 P8005 Q76649614 @default.
- Q93581660 P8363 Q78089383 @default.
- Q93581660 P859 Q731938 @default.